Zydus Lifesciences has announced its financial results for the first quarter of FY27, reporting a 22% year-on-year increase in total revenues to ₹80,170 million. The company’s EBITDA stood at ₹19,294 million, while Net Profit was ₹9,398 million. Key growth drivers included strong performance in India Formulations, North America, and International Markets.
Zydus Lifesciences Reports Strong Q1 FY27 Performance
Zydus Lifesciences Limited has reported robust financial results for the first quarter ended June 30, 2026, showcasing significant growth across its key business segments. Total revenues from operations for Q1 FY27 increased by 22% YoY to reach ₹80,170 million. This growth was driven by a consolidated sales performance of ₹78,020 million, up 21% YoY.
Key Financial Highlights
- Revenues from Operations: ₹80,170 million (+22% YoY)
- EBITDA: ₹19,294 million (24.1% margin, down 770 bps YoY)
- Net Profit: ₹9,398 million (-35.9% YoY)
- Total R&D expenses: ₹6,424 million (8% of revenues)
- Capex (organic): ₹5,852 million
- Net Debt: ₹59,041 million (as at 30-Jun’26)
Segment Performance
The India Formulations business saw sales of ₹18,158 million in Q1 FY27, representing a 19.5% YoY growth. The business continues to outperform IPM in key therapies and has seen its chronic and sub-chronic portfolio grow to 54.2%. The North America Formulations business reported sales of ₹30,979 million, a slight decrease of -2.6% YoY but a 4.9% QoQ growth, driven by volume expansion and new launches. The International Markets business achieved sales of ₹9,735 million, marking a substantial 34.0% YoY increase and 21.1% QoQ growth. The Consumer Wellness segment reported sales of ₹14,292 million, with a remarkable 67.2% YoY growth, though a -2.3% QoQ decline. Key brands in India continue to hold dominant market share.
Regulatory Updates
The company noted that its injectable manufacturing facility at Zydus Biotech Park received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification following a GMP surveillance inspection.
Innovation and R&D
In NCE Research, the USFDA granted priority review for the NDA of Saroglitazar Magnesium. In Biotech R&D, Phase III clinical trials for the company’s second biosimilar antibody drug conjugate were initiated. For Vaccines R&D, Phase II clinical trials of a bivalent Typhoid Conjugate vaccine were completed.
Source: BSE
